Alligator Bioscience AB Market Cap ($1.10 Million)
Market Cap & Net Worth: Alligator Bioscience AB (ATORX)
Alligator Bioscience AB market cap. Alligator Bioscience AB (ST:ATORX) has a market capitalization of $1.10 Million (Skr10.26 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #30604 globally and #700 in its home market, demonstrating a 3.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alligator Bioscience AB's stock price Skr0.01 by its total outstanding shares 924614628 (924.61 Million). Also see Alligator Bioscience AB (ATORX) cash conversion ratio for how efficiently the company converts equity into cash flow.
Alligator Bioscience AB Market Cap History (2016–2026)
Alligator Bioscience AB market cap history from 2016 to 2026. Data shows change from $3.46 Billion to $1.10 Million (-55.87% CAGR). Check latest Alligator Bioscience AB stock price today for real-time trading data and today's change.
Alligator Bioscience AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alligator Bioscience AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ATORX year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
65.22x
Alligator Bioscience AB's market cap is 65.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.46 Billion | $58.24 Million | -$48.36 Million | 59.46x | N/A |
| 2017 | $2.32 Billion | $56.88 Million | -$63.76 Million | 40.76x | N/A |
| 2018 | $2.19 Billion | $26.96 Million | -$150.04 Million | 81.20x | N/A |
| 2019 | $1.05 Billion | $4.36 Million | -$210.53 Million | 241.11x | N/A |
| 2020 | $758.71 Million | $4.35 Million | -$143.61 Million | 174.34x | N/A |
| 2021 | $255.72 Million | $12.94 Million | -$141.74 Million | 19.76x | N/A |
| 2022 | $154.23 Million | $35.70 Million | -$193.40 Million | 4.32x | N/A |
| 2023 | $68.56 Million | $58.11 Million | -$248.59 Million | 1.18x | N/A |
| 2024 | $24.78 Million | $57.77 Million | -$233.89 Million | 0.43x | N/A |
| 2025 | $33.52 Million | $514.00K | -$51.35 Million | 65.22x | N/A |
Competitor Companies of ATORX by Market Capitalization
Companies near Alligator Bioscience AB in the global market cap rankings as of November 4, 2026. Also see ATORX asset base for a full breakdown of the balance sheet.
Key companies related to Alligator Bioscience AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Alligator Bioscience AB (2016–2026)
Market capitalization of Alligator Bioscience AB from 2016 to today. Between 2016 and today, Alligator Bioscience AB's market cap moved from $3.46 Billion to $ 1.10 Million, with a yearly change of -55.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr1.10 Million | -96.71% |
| 2025 | Skr33.52 Million | +35.30% |
| 2024 | Skr24.78 Million | -63.86% |
| 2023 | Skr68.56 Million | -55.55% |
| 2022 | Skr154.23 Million | -39.69% |
| 2021 | Skr255.72 Million | -66.30% |
| 2020 | Skr758.71 Million | -27.79% |
| 2019 | Skr1.05 Billion | -52.00% |
| 2018 | Skr2.19 Billion | -5.58% |
| 2017 | Skr2.32 Billion | -33.05% |
| 2016 | Skr3.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Alligator Bioscience AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.10 Million USD |
| MoneyControl | $1.10 Million USD |
| MarketWatch | $1.10 Million USD |
| marketcap.company | $1.10 Million USD |
| Reuters | $1.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using N… Read more